-- 週四下午，醫療保健類股普遍下跌，紐約證券交易所醫療保健指數和道富醫療保健精選行業SPDR ETF (XLV) 均下跌0.7%。 iShares生物科技ETF (IBB) 下跌2.6%。 公司新聞方面，Iovance Biotherapeutics (IOVA) 股價下跌超過13%，此前該公司公佈的第一季虧損收窄幅度小於預期，且營收不及預期。 Harmony Biosciences (HRMY) 股價下跌5%，此前該公司公佈的第一季獲利和營收均低於分析師預期。 Catalyst Pharmaceuticals (CPRX) 股價上漲2.2%，此前該公司同意被Angelini Pharma以約41億美元的股權價值收購。該公司還表示，已與Hetero Labs達成和解協議，以解決有關Firdapse仿製藥的專利訴訟。
Related Articles
Research
Research Alert: CFRA Keeps Buy Opinion On Shares Of Antero Resources Corporation
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target remains $48, a 6x multiple of enterprise value to our 2027 EBITDA estimate, in line with AR's historical forward average. We raise our 2026 EPS estimate by $1.11 to $4.37 and our 2027 EPS estimate by $0.76 to $4.90. We see AR as a leading provider of relatively low-cost natural gas, as well as a healthy degree of NGL exposure. Management is 45% hedged in 2026 in the $3.90/MMBtu range, but that hedge protection drops to about the 30% range for 2027. Following the pending Ohio Utica divestiture, and the now-completed HG deal, AR's exposure to the Marcellus only rises. We see the Marcellus as a relatively lower-cost gas play. AR ended 2025 with a net debt-to-EBITDA ratio of just 2.1x, down from 4.9x at the end of 2024, and yielding considerably improved financial flexibility in our view. We estimate that shares are trading at a sizable discount to AR's historical forward average, despite our view that earnings power should improve to nearly 2022-era levels.
$AR
Research
Research Alert: CFRA Maintains Hold Opinion On Owens Corning With A $136 Target Price
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We maintain our target price of $136. Our target is an average of a forward P/E of 8.5x our 2027 EPS view of $12.72 ($108) and our DCF model, using a terminal growth rate of 2.5%, WACC of 7.1%, and 10-year FCFF CAGR of 7.7% ($164). Q1 was particularly weak across all segments, with revenues down 10% and EBITDA down 35%. Margins also compressed 600 basis points, however looking through the weakness, Q2 margins are expected to improve to the 20-22% range ($2.6B-$2.7B). This in combination with the glass reinforcements sale ($280M in cash) being completed may be why shares are responding positively in pre-market trading.
$OC
Insider Trading
Globe Life Insider Sold Shares Worth $333,656, According to a Recent SEC Filing
Michael Shane Henrie, Senior Vice President & Chief Accounting Officer, on May 06, 2026, sold 2,150 shares in Globe Life (GL) for $333,656. Following the Form 4 filing with the SEC, Henrie has control over a total of 3,609 common shares of the company, with 3,449 shares held directly and 160 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/320335/000032033526000167/xslF345X05/form4.xmlPrice: $152.59, Change: $-1.80, Percent Change: -1.17%
$GL